Dual VEGF inhibition with sorafenib and bevacizumab as salvage therapy in metastatic colorectal cancer: results of the phase II North Central Cancer Treatment Group study N054C (Alliance)

BACKGROUND: Bevacizumab (BEV), a monoclonal antibody against vascular endothelial growth factor-A (VEGF-A), is a standard component of medical therapy of metastatic colorectal cancer (mCRC). Activation of alternative angiogenesis pathways has been implicated in resistance to BEV. This phase II study...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Ther Adv Med Oncol
Autori principali: Xie, Hao, Lafky, Jacqueline M., Morlan, Bruce W., Stella, Philip J., Dakhil, Shaker R., Gross, Gerald G., Loui, William S., Hubbard, Joleen M., Alberts, Steven R., Grothey, Axel
Natura: Artigo
Lingua:Inglês
Pubblicazione: SAGE Publications 2020
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7066587/
https://ncbi.nlm.nih.gov/pubmed/32201506
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835920910913
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi